This suggests that circadian rhythms could dramatically influence the effectiveness of HIF2α antagonists in ccRCC, either due to tumor-intrinsic expression of BMAL1 or other physiological rhythms. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.